Diabetes und Metabolische Dysfunktion-assoziierte Steatotische Lebererkrankung

Aktualisierungshinweis

Die DDG-Praxisempfehlungen werden regelmäßig zur zweiten Jahreshälfte aktualisiert. Bitte stellen Sie sicher, dass Sie jeweils die neueste Version lesen und zitieren.

Publikationsverlauf

Artikel online veröffentlicht:
21. November 2024

• Literatur

• 1 Younossi ZM, Golabi P, Paik JM. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77: 1335-1347
• 2 Estes C, Anstee QM, Arias-Loste MT. et al. Modeling MASLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 2018; 69: 896-904
• 3 Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 2022; 10: 284-296
• 4 Younossi ZM, Golabi P, Price JK. et al. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol 2024; 21
• 5 Njei B, Al-Ajlouni YA, Ugwednum D. et al. Genetic and epigenetic determinants of non-alcoholic fatty liver disease (NAFLD) in lean individuals: a systematic review. Transl Gastroenterol Hepatol 2023; 9: 11
• 6 Eigentler T, Lomberg D, Machann J. et al. Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade. Ann Intern Med 2020; 172: 836-837
• 7 Abeysekera KWM, Valenti L, Younossi Z. et al. Implementation of a liver health check in people with type 2 diabetes. Lancet Gastroenterol Hepatol 2024; 9: 83-91
• 8 Zaharia OP, Strassburger K, Strom A. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694
• 9 Rinella ME, Lazarus JV, Ratziu V. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78: 1966-1986
• 10 Roeb E, Canbay A, Bantel H. et al. Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025. Z Gastroenterol 2022; 60: 1346-1421
• 11 European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity; Clinical Practice Guideline Panel. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia 2024; 67: 2375-2392
• 12 European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 2021; 75: 659-689
• 13 Younossi ZM, Corey KE, Alkhouri N. et al. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther 2020; 52: 513-526
• 14 Tilg H, Moschen AR, Roden M. MASLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017; 14: 32-42
• 15 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357
• 16 Bril F, McPhaul MJ, Caulfield MP. et al. Performance of the SteatoTest, ActiTest, MASHTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med 2019; 67: 303-311
• 17 Singh S, Allen AM, Wang Z. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-654.e1–9
• 18 Kim J, Seki E. Unveiling the cancer risk nexus of the steatotic liver. Trends Endocrinol Metab 2024; 25
• 19 Adams LA, Anstee QM, Tilg H. et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138-1153
• 20 Aminian A, Al-Kurd A, Wilson R. et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA 2021; 326: 2031-2042
• 21 Newsome PN, Buchholtz K, Cusi K. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384: 1113-1124
• 22 Loomba R, Abdelmalek MF, Armstrong MJ. et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 2023; 8: 511-522
• 23 Loomba R, Hartman ML, Lawitz EJ. et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med 2024; 391: 299-310
• 24 Sanyal AJ, Pierre B, Fraessdorf M. et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med 2024; 391: 311-319
• 25 Francque SM, Bedossa P, Ratziu V. et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in MASH. N Engl J Med 2021; 385: 1547-1558
• 26 Loomba R, Sanyal AJ, Kowdley KV. et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in MASH. N Engl J Med 2023; 389: 998-1008
• 27 Hrrison SA, Bedossa P, Guy CD. et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med 2024; 390: 497-509
• 28 FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. FDA 14.03.2024, abgerufen am 02.07.2024.